Literature DB >> 12116246

Novel mutation in the Delta-sterol reductase gene in three Lebanese sibs with Smith-Lemli-Opitz (RSH) syndrome.

Marjan M Nezarati1, Judith Loeffler, Grace Yoon, Linda MacLaren, Ernest Fung, Floyd Snyder, Gerd Utermann, Gail E Graham.   

Abstract

The Smith-Lemli-Opitz syndrome (SLOS), or RSH syndrome, is a well-characterized multiple congenital anomalies/mental retardation syndrome. The phenotype has been redefined to include mildly affected individuals with minor anomalies and developmental delay, and severe malformations with pre- and perinatal mortality. The condition is due to the deficient activity of the enzyme 7-dehydrocholesterol (7-DHC) reductase [Shefer et al., 1995: J Clin Invest 96:1779-1785], and the gene has been mapped to chromosome 11q13 [Moebius et al., 1998: Proc Natl Acad Sci USA 95:1899-1902]. We describe here a consanguineous family of Syrian-Lebanese ancestry with three sibs affected with SLOS: two with a mild variant, while the other had severe disease and died in the first year of life. Mutation analysis demonstrated a novel mutation in the DHCR7 gene, present in homozygous form in the two affected individuals available for testing, and heterozygous in the parents. The wide intrafamilial variation of clinical severity in these three sibs is an important finding in SLOS. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116246     DOI: 10.1002/ajmg.10367

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

1.  A review of the diverse genetic disorders in the Lebanese population: highlighting the urgency for community genetic services.

Authors:  Ghunwa Nakouzi; Khalil Kreidieh; Soha Yazbek
Journal:  J Community Genet       Date:  2014-09-27

2.  Adrenal function in Smith-Lemli-Opitz syndrome.

Authors:  Simona E Bianconi; Sandra K Conley; Meg F Keil; Ninet Sinaii; Kristina I Rother; Forbes D Porter; Constantine A Stratakis
Journal:  Am J Med Genet A       Date:  2011-10-11       Impact factor: 2.802

3.  Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome.

Authors:  M Witsch-Baumgartner; M Gruber; H G Kraft; M Rossi; P Clayton; M Giros; D Haas; R I Kelley; M Krajewska-Walasek; G Utermann
Journal:  J Med Genet       Date:  2004-08       Impact factor: 6.318

4.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

Review 5.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.